Management of myelodysplastic syndromes after failure of response to hypomethylating agents.

Although less than 30% of the AZA patients completed the planned 12 cycles, the study showed a trend toward improvement in RFS in the patients receiving more AZA cycles. 101 Maintenance with CC-486, a novel oral AZA formulation that allows extended dosing and prolonged activity, has also been explored, although with limited data on frequency of prior therapy with HMAs. 98 Thirty patients in CR after alloSCT received CC-486 once daily for 7 or 14 days in a 28-day cycle for up to 12 cycles and among these, 9 had received AZA prior to transplant.

also in 53,322 other papers